Skip to main content

Market Overview

Benzinga's Top Upgrades with Color for May 11, 2012

Share:

Listed below are today's Top Upgrades at Benzinga:

Goldman Sachs Upgrades Incyte (NASDAQ: INCY) to Buy:

Goldman Sachs said, "We are more bullish given the strong Jakafi launch (approved for niche blood cancer, myelofibrosis (MF), partnered with NVS) and significant derisking of key pipeline asset LY3009104 (‘104, partnered with LLY, an oral Phase II drug for rheumatoid arthritis (RA)). ‘104's potential was validated with the positive FDA panel vote on May 9 on Pfizer's tofacitinib (tofa, in the same drug class (JAK inhibitor)). In addition, we now see INCY as a more attractive M&A candidate with a marketed drug and a potential blockbuster pipeline asset."

Jefferies & Company Upgrades Arena Pharmaceuticals (NASDAQ: ARNA) to Buy from Underperform:

Jefferies said, "Based on the positive outcomes in yesterday's panel (18-4 vote), but more so on the positive FDA and panel commentary on the critical CV MACE question, we believe lorcaserin is likely to receive approval on the June 27 decision date. Based on the prospects for combination usage with phentermine, we assume $1.5b in 2020 sales and are raising our price target from $1 to $9."

Credit Suisse Upgrades Sun Life Financial (NYSE: SLF) to Outperform: Credit Suisse said, "Upcoming earnings/capital charges are downplayed. (1) New seg fund calibration rules are expected to have a modest impact (management ball parked $30 million); (2) guidance suggests no material need to strengthen U.S. VA lapse assumptions; and (3) management has already guided to a $60 million potential hit from URR reserve strengthening. Overall, SLF's outlook suggests significantly smaller earnings/capital charges than peers (notably MFC), which increases the stock's near-term appeal."

Credit Suisse Upgrades Bed Bath & Beyond (NASDAQ: BBBY) to Outperform:

Credit Suisse said, "We are upgrading Bed Bath & Beyond to Outperform (from Neutral) as we believe the acquisition of Cost Plus adds some significant growth potential to what is already a very compelling but slowing growth story. Specifically, at a time of investor concern over Internet competition and tougher comparisons, this acquisition should significantly advance direct sourcing and unique merchandising opportunities for BBBY, provide a key driver for incremental comps within BBBY, improve selection and lower sourcing costs, and also help the assortment within the current World Market stores."

All of Benzinga's Analyst Ratings news can be viewed here.

Latest Ratings for INCY

DateFirmActionFromTo
Feb 2021Morgan StanleyMaintainsEqual-Weight
Feb 2021SVB LeerinkDowngradesMarket PerformUnderperform
Jan 2021Truist SecuritiesInitiates Coverage OnBuy

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

 

Related Articles (INCY)

View Comments and Join the Discussion!

Posted-In: Credit Suisse Goldman Sachs Jefferies & CompanyAnalyst Color Upgrades Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
IRIXRoth CapitalMaintains9.0
AMRSRoth CapitalMaintains33.0
VORBarclaysInitiates Coverage On56.0
PNMCitigroupDowngrades
UBSFYCitigroupUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com